13th International Symposium on Minimal Residual Cancer 2023
Scientific Programme

Scientific Programme

Day 1 | Tuesday, 2 May 2023

From 7:30 a.m.Registration Counter open 
09:00 - 09:30 a.m.Opening remarksKlaus Pantel, Germany & 
Catherine Alix-Panabières, France
 Welcome address of the dean of the University Medical Centre HamburgBlanche Schwappach-Pignataro, Germany     
   
Session 1Cancer BiologyChairs: 
Catherine Alix-Panabières, France
Christoph Wagener, Germany
09:30 - 10:00 a.m.

Mechanisms of Metastatic Awakening

Abstract

Robert Weinberg, USA
10:00 - 10:30 a.m.

Circulating Tumor Cell Clusters

Abstract

Nicola Aceto, Switzerland
10:30 - 11:00 a.m.Tumor-derived extracellular vesicle DNA: novel configuration and 
immune regulation in cancer
David Lyden, USA
11:00 - 11:15 a.m.

Understanding the biomechanics of colon metastasis-competent 
CTCs using microchips mimicking microcapillaries of the bloodstream

Abstract

Keerthi Kurma, France
11:15 - 11:30 a.m.

Deciphering the methylation signature of circulating extracellular 
vesicle DNA and cell-free DNA for CNS tumor classification

Abstract

Franz Ricklefs, Germany
11:30 - 11:45 a.m.Coffee Break 
   
Session 2Cancer ImmunologyChairs:
Klaus Pantel, Germany
Samuel Huber, Germany
11:45 a.m. - 12:30 p.m.

Insights from a thirty-year journey of PD-1: function, regulation and 
therapeutic modulation

Abstract

Keynote by Tasuko Honjo, 
Nobel Laureate 2018, Japan
12:30 - 01:00 p.m.  Gut microbiota fingerprint predicting resistance to cancer immunotherapyLaurence Zitvogel, France
01:00 - 01:15 p.m.         

Treatment response monitoring using cell-free DNA fragmentation profiling

Abstract

Remond Fijneman, The Netherlands
01:15 - 01:30 p.m.

Single cell transcriptome atlas reveals a high degree of hetereogeneity in 
NSCLC circulating tumor cells

Abstract

Melanie Janning, Germany
01:30 - 02:45 p.m.Lunch Break 
   
Session 3Liquid Biopsy-Based Detection of Primary Cancer & Minimal 
Residual Cancer – Part I
Chairs:
Nikolas von Bubnoff, Germany
Stefan Schneider, Germany
02:45 - 03:15 p.m.Clinical applications of MRDNickolas Papadopoulos, USA
03:15 - 03:45 p.m.

Liquid Biopsy: From Discovery to Clinical implementation

Abstract

Klaus Pantel, Germany
03:45 - 04:00 p.m.

A whole leukocyte-DNA methylome risk score to predict pancreatic 
cancer

Abstract

Evangelina López De Maturana, Spain
04:00 - 04:15 p.m.

A data-driven approach employing automated Machine Learning 
reveals novel liquid biopsy methylation biomarkers for breast cancer

Abstract

Ekaterini Alexiou Chatzaki, Greece
04:15 - 06:15 p.m.Poster Session with Coffee 
   

 

Day 2 | Wednesday, 3 May 2023

Session 4Liquid Biopsy and Immuno-OncologyChairs: 
Christoffer Gebhardt, Germany
Paul Hofman, France
09:00 - 09:30 a.m.Targeting mismatch repair with immunotherapyLuis Diaz, USA
09:30 - 10:00 a.m.

The power of circulating tumor cells in Immuno-Oncology

Abstract

Catherine Alix-Panabières, France                   
10:00 - 10:15 a.m.

Circulating cell-free DNA and circulating tumor cells as prognostic 
biomarkers in stage III melanoma

Abstract

Anthony Lucci, USA
10:15 - 10:30 a.m.

Circulating tumor DNA (ctDNA) as sensitive and specific biomarker in 
stage I to III malignant melanoma

Abstract

Eva Dazert-Klebsattel, Germany
10:30 - 11:30 a.m.Coffee Break 
   
Session 5Immunotherapy for Prevention of Metastatic Progression – Part I           Chairs:
Katja Weisel, Germany
Laurence Zitvogel, France
11:30 a.m. - 12:00 p.m.

Claudin6-directed therapy approaches in solid tumors

Abstract

Carsten Bokemeyer, Germany
12:00 - 12:15 p.m.

Targeting the AKT/mTOR pathway attenuates the metastatic potential 
of  colorectal carcinoma CTCs in a murine xenotransplantation model 
and alters metabolic pathways

Abstract

Daniel J. Smit, Germany
12:15 - 12:30 p.m.

Circulating tumor cell enumeration and ultradeep T-cell receptor-
sequencing in a Phase I clinical trial of metastatic prostate cancer

Abstract

Karl-Henning Kalland, Norway
12:30 - 01:00 p.m.

Harnessing Natural Killer cells in cancer

Abstract

Eric Vivier, France
01:00 - 02:00 p.m.Lunch Break 
   
Session 6Liquid Biopsy-Based Detection of Primary Cancer & Minimal 
Residual Cancer – Part II
Chairs:
Matthias Löhr, Sweden
Thilo Hackert, Germany
02:00 - 02:30 p.m.

Pushing the boundaries to expand diagnostic applications of circulating 
DNA

Abstract

Nitzan Rosenfeld, UK
02:30 - 03:00 p.m.

Integration of liquid biopsies into molecular tumor boards

Abstract

Ellen Heitzer, Austria
03:00- 03:30 p.m.

Circulating Tumor DNA for Minimal Residual Disease Detection and 
Risk-Stratified Recurrence Surveillance in Colorectal Cancer

Abstract

Claus Lindbjerg Andersen, Denmark
03:30 - 03:45 p.m.

Potential clinical utility of circulating tumor DNA detected by digital PCR 
in anationwide Danish cohort of high-risk colorectal cancer patients

Abstract

Tenna Henriksen, Denmark
03:45 - 04:00 p.m.

Personalised analysis of cell-free circulating tumour DNA for detection of 
molecular residual disease and recurrence in patients with head and 
neck squamous cell carcinoma: the LIONESS study

Abstract

Susanne Flach, Germany
04:00 - 04:30 p.m.Rita Zamarchi Award SessionChair: 
Maria Chiara Scaini, Italy
04:30 - 06:30 p.m.Poster Session with Coffee 
   

 

Day 3 | Thursday, 4 May 2023

Session 7Latest developments in Liquid biopsy-based monitoring of MRD   Chairs:
Ellen Heitzer, Austria
Claus Lindbjerg Andersen, Denmark
09:00 - 09:20 a.m.

Screening of patient samples with advanced Non-Small Cell Lung Cancer 
in Circulating Cell-Free DNA using Three Targeted Assays

Abstract

Lea Payen, France
09:20 - 09:40 a.m.

Standardizing and harmonizing MRD assessment using ctDNA to enable 
clinical implementation to improve patient outcomes

Abstract

Mohan Bolisetty, USA
09:40 - 10:00 a.m.

Comprehensive liquid biopsy analysis as a tool for early detection of 
minimal residual disease in breast cancer

Abstract

Athina Markou, Greece
10:00 - 10:30 a.m.Coffee Break 
   
Session 8Immunotherapy for prevention of metastatic progression – Part II          Chairs: 
Simon Joosse, Germany
Gunhild von Amsberg, Germany
10:30 - 11:00 a.m.

Immunotherapy of Lung Cancer – Current Status in metastatic
and non-metastatic NSCLC

Abstract

Martin Reck, Germany
11:00 - 11:30 a.m.

Liquid biopsy & lung cancer immunotherapy: Between hope 
and hype in routine practice

Abstract

Paul Hofman, France
11:30 a.m. - 12:00 p.m.Omics-driven identification of therapeutic resistance in metastatic
melanoma patients receiving immune checkpoint inhibition
Christoffer Gebhardt,  Germany                      
12:00 - 12:30 p.m.

Outlook of clinical applications of Liquid Biopsy

Abstract

Howard Scher, USA
12:30 - 01:00 p.m.Young Investigator AwardsChairs:
Klaus Pantel, Germany & 
Catherine Alix-Panabières, France
01:00 - 01:15 p.m.Concluding RemarksKlaus Pantel, Germany & 
Catherine Alix-Panabières, France